Upbeat Celgene Data Not Enough to Lift Biotech Sector

Upbeat Celgene Data Not Enough to Lift Biotech Sector


Shares of Celgene and Acceleron Pharma are climbing on Tuesday, after announcing that Luspatercept, the anemia drug the biotech firms are jointly developing, performed well in a Phase III study. The news isn't entirely a surprise, as analysts were expecting positive results, due to data from a previous study that supported the drug's chances of success.



from Biotech News